Table 2.

Logistic regression analysis to identify factors associated with MRA prescription

		Eligible		Ineligible
		OR (95 % CI)	Adjusted p-value	OR (95 % CI)	Adjusted p-value
Demographics	Age	1.01 (0.98–1.03)	0.69	1.00 (0.98–1.02)	0.91
	Female	0.97 (0.51–1.83)	0.92	2.22 (1.27–3.88)	0.01
	Length of stay	1.01 (0.99–1.02)	0.33	1.01 (0.99–1.03)	0.17
Medical history	Heart failure	1.66 (0.83–3.32)	0.15	2.38 (0.97–5.85)	0.06
	Hypertension	0.99 (0.56–1.75)	0.97	1.24 (0.70–2.17)	0.46
	Dyslipidemia	0.47 (0.26–0.85)	0.01	0.73 (0.41–1.29)	0.40
	Diabetes	1.06 (0.61–1.83)	0.84	1.33 (0.69–2.56)	0.28
	Smoking	1.84 (1.03–3.27)	0.04	1.39 (0.81–2.39)	0.23
	MI	0.99 (0.50–1.95)	0.98	1.05 (0.54–2.03)	0.89
Clinical data	SBP	0.99 (0.97–1.00)	0.16	1.00 (0.99–1.01)	0.58
	Heart rate	1.01 (0.99–1.03)	0.17	0.99 (0.97–1.01)	0.40
	LVEF	0.93 (0.90–0.97)	0.00	0.93 (0.90–0.96)	0.00
	STEMI	1.44 (0.74–2.80)	0.28	1.62 (0.85–3.10)	0.15
Laboratory data	Troponin T	1.02 (0.97–1.07)	0.39	1.05 (1.00–1.09)	0.05
	Potassium	0.50 (0.23–1.08)	0.08	1.01 (0.56–1.79)	0.99
	Estimated GFR	1.00 (0.99–1.01)	0.87	1.00 (0.99–1.01)	0.74

Analysis of factors associated with increased rates of MRA prescription. CI, confidence interval; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; μg/L, micrograms per liter; μmol/L, micromole per liter; mmHg, millimeters mercury; mmol/L, millimoles per liter; OR, odds ratio; STEMI, ST elevation myocardial infarction; SBP, systolic blood pressure